Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2013: Transmitted Antiretroviral Drug Resistance Holds Steady at 16% [VIDEO]

Approximately 1 in 6 analyzed HIV sequences showed evidence of antiretroviral drug resistance, with NNRTIs being particularly vulnerable, according to a CDC analysis presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

CROI 2013: Functional Cure of HIV-infected Infant after Early ART [VIDEO]

The big news on the opening day of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) was a report about an infant with HIV who started combination antiretroviral treatment very early and now shows no evidence of replication-competent virus. "We equate this to our Berlin Patient," said Deborah Persaud from Johns Hopkins University School of Medicine. "It could get us on the road to a cure for HIV-infected children."alt

Read more:

CROI 2013: MK-1439 -- A Novel NNRTI For HIV Treatment [VIDEO]

A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated good antiretroviral activity and tolerability as 7-day monotherapy in a small Phase 1b trial, researchers reported at the 20th Conference  on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more:

CROI 2013: Second-line NRTI-sparing HIV Regimen Proves Equally Effective

A second-line antiretroviral regimen of lopinavir/ritonavir (Kaletra or Aluvia) and raltegravir (Isentress) proved just as effective as a regimen containing lopinavir/ritonavir and 2 or 3 nucleoside or nucleotide analogs in large study conducted in Australia, Africa, Latin America, and Asia, researchers from Sydney’s Kirby Institute reported this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

CROI 2013: Challenges and Opportunities for the Development of Long-acting Antiretrovirals [VIDEO]

Marta Boffito from Chelsea and Westminster Hospital in London presented an overview of some of the challenges and opportunities in the development of long-acting antiretroviral agents for HIV treatment and prevention in a themed discussion at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more:

CROI 2013: Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort

A large French study has found an elevated risk of some birth defects in children born to women exposed to some antiretroviral drugs during the first trimester of pregnancy, French researchers reported on at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.

alt

Read more:

CROI 2013: Can HIV Elite Controllers Benefit from Antiretroviral Treatment?

Elite controllers -- people who naturally maintain undetectable viral load without antiretroviral therapy (ART) -- experienced decreased levels of HIV genetic material and reductions in markers of inflammation and immune activation after starting experimental treatment, according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more: